Madrid, here we come! 🇪🇸 Iovance’s 5 abstracts at #ESMO26 (Oct 23–27) showcase the TIL platform, including 2 orals in frontline advanced melanoma 🔬 and refractory soft tissue sarcomas 🧬 Details here: https://t.co/KcexlTTiTN https://t.co/CQ1M6BCFyU